Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
Rhea-AI Summary
Evogene (NASDAQ: EVGN) received a Nasdaq notice for noncompliance with the $1.00 minimum bid price rule after its closing bid remained below $1.00 for 30 consecutive business days.
The company has a 180-calendar-day cure period ending September 28, 2026 to regain compliance (10 consecutive business days at $1.00+). Trading will continue on Nasdaq during the cure period, and Evogene may consider options including a reverse stock split if needed.
AI-generated analysis. Not financial advice.
Positive
- Trading continues on Nasdaq during cure period
- 180-day cure period through September 28, 2026 to regain compliance
- Eligibility for additional 180 days if other listing standards are met
Negative
- Closing bid price below $1.00 for 30 consecutive business days
- Risk of delisting if compliance not achieved by September 28, 2026
- Possible reverse stock split or other shareholder-impacting action may be considered
News Market Reaction – EVGN
On the day this news was published, EVGN declined 0.41%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
EVGN was up 5.06% while biotech peers showed mixed moves: ERNA +2.53%, MBIO +4.41%, KZIA -2.05%, MBRX -1.33%, LYRA roughly flat at +0.02%, indicating stock-specific dynamics rather than a clear sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Subsidiary field trials | Positive | +4.8% | Casterra reported successful commercial castor field trials across 74 hectares in Brazil. |
| Mar 09 | Conference presentation | Positive | -0.4% | Company highlighted pharma discovery achievements and ChemPass AI at BIO-Europe Spring. |
| Mar 05 | Earnings results | Negative | -6.2% | Reported 2025 loss, inventory impairment, restructurings and reliance on warrant proceeds. |
| Feb 25 | CEO strategic letter | Positive | +4.6% | Outlined strategic refocus on ChemPass AI and divestiture of non-core assets. |
| Feb 19 | Earnings call schedule | Neutral | -5.6% | Announced timing and access details for upcoming 2025 results release. |
Recent EVGN news often produced sizable moves in both directions, with some divergence around neutral or event-type announcements while operational and financial updates tended to align with price direction.
Over the last few months, EVGN has alternated between strategic updates and financial disclosures. A CEO letter on Feb 25, 2026 and Casterra’s Brazil field‑trial success on Mar 31, 2026 both coincided with positive price moves. In contrast, the Mar 5, 2026 full‑year 2025 results and a Feb 19, 2026 earnings scheduling release saw negative reactions. The BIO-Europe presentation announcement on Mar 9, 2026 was followed by a slight decline. Today’s Nasdaq bid‑price notice adds a listing‑risk layer on top of this existing operational and financial backdrop.
Regulatory & Risk Context
An effective F-3 shelf dated 2026-03-26 registers 5,076,924 ordinary shares for resale tied to warrants. The company would receive $6.35 million only if these warrants are exercised in full for cash, while secondary resales by the selling shareholder would not provide proceeds to Evogene. The filing also notes a 4.99% beneficial ownership limitation on the warrants.
Market Pulse Summary
This announcement highlights that EVGN’s Nasdaq closing bid has stayed below $1.00 for 30 consecutive business days, triggering a formal 180‑day cure period ending on September 28, 2026. Compliance requires at least 10 consecutive trading days with a bid of $1.00 or more, with a possible additional 180‑day extension. Investors may watch for any actions the company might take, such as a reverse stock split, alongside existing F‑3 warrant‑related resale capacity and recent going‑concern and restructuring disclosures.
Key Terms
minimum bid price requirement regulatory
nasdaq capital market regulatory
reverse stock split financial
AI-generated analysis. Not financial advice.
REHOVOT,
The Nasdaq Stock Market Rules provide the Company a period of 180 calendar days to regain compliance. According to the Letter, the Company has until September 28, 2026, to regain compliance with the minimum bid price requirement. The Company will regain compliance, if at any time during this 180-day period, the closing bid price of its ordinary shares is at least
If the Company does not demonstrate compliance prior to the end of the 180-day period ending September 28, 2026, the Nasdaq staff will notify the Company that its ordinary shares will be subject to delisting.
However, the Company may then be eligible for additional time to regain compliance, of up to a further 180 calendar days, if it meets the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement. To be eligible, the Company will also need to provide further written notice of its intention to cure the deficiency during the second compliance period.
It is noted that Evogene's continued listing on Nasdaq remains a key priority for the Company. Should the situation not resolve itself over the above-mentioned timeframe, the Company intends to consider other available options to cure the deficiency and regain compliance with the minimum bid requirement within the compliance period, including potentially approving a reverse stock split, among other alternatives.
The Letter from Nasdaq has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares on Nasdaq, and during the aforementioned cure period, as may be extended, the Company's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "EVGN". It is further noted that the Letter from Nasdaq has no bearing on Evogene's listing on the Tel Aviv Stock Exchange, where its ordinary shares are traded under the ticker symbol "EVGN".
About Evogene Ltd.
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AITM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. By integrating AI-driven molecular design with experimental validation, ChemPass AI™ enables the efficient discovery of differentiated small-molecule candidates with improved probability of development success. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene has utilized forward-looking statements in this press release when it discusses its ability to regain compliance with Nasdaq's Listing Qualification requirements including by potentially effecting a reverse stock split to regain compliance with the
Evogene Investor Relations Contact:
Email: ir@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-reports-receipt-of-nasdaq-minimum-bid-price-notification-302732572.html
SOURCE Evogene